|March 14, 2014|
|14:55 EDT||BIIB, BIIB, BIIB, AEP, AEP, AEP||Biogen to replace American Electric in S&P 100 as of 3/21 close|
News For BIIB;AEP From The Last 14 Days
Check below for free stories on BIIB;AEP the last two weeks.
|August 27, 2014|
|09:08 EDT||BIIB||Nektar could see $100M in revenue from Baxter drug, says Roth Capital|
Roth Capital believes that Baxter's (BAX) BAX-855 drug delivered compelling Phase III data, and the firm expects the drug to compete effectively against Biogen's (BIIB) Eloctate. Roth expects BAX-855 to launch in 1Q16 and believes it could generate up to $100M in annual revenue for Nektar. The firm keeps a $21 price target and Buy rating on Nektar.
|08:21 EDT||BIIB||NICE recommends Tecfidera for multiple sclerosis|
Dimethyl fumarate is recommended as a possible treatment for people with active relapsing-remitting multiple sclerosis that isn't highly active or rapidly evolving severe relapsing-remitting multiple sclerosis, the U.K.'s National Institute for Health and Care Excellence stated in guidance posted to its website. Reference Link
|August 26, 2014|
|11:21 EDT||BIIB||Biogen added to short term buy list at Deutsche Bank|
|August 25, 2014|
|12:06 EDT||AEP||American Electric reaffirms FY14 operating EPS view $3.35-$3.55, consensus $3.49|
American Electric Power announced Brian Tierney, AEP executive vice president and CFO, will present at the Barclays CEO Energy-Power Conference Sept. 3. During the conference, AEP will reaffirm its 2014 operating earnings guidance of $3.35 to $3.55 per share.
|August 22, 2014|
|12:39 EDT||BIIB||These five companies will benefit from increased ALS awareness, MarketWatch says|
A recent surge in funding for Lou Gehrig's disease, or ALS, caused by the Ice Bucket challenge that is widespread on social media outlets, will benefit five pharmaceutical companies that are involved in the development of a cure for ALS, according to MarketWatch. The companies that are or have been involved in developing a treatment for ALS include Biogen Idec (BIIB), Avanir Pharmaceuticals (AVNR), Isis Pharmaceuticals (ISIS), Sanofi (SNY), and Bristol-Myers Squibb (BMY), MarketWatch added. Reference Link
|August 20, 2014|
|07:10 EDT||AEP||American Electric total return outlook compelling, says Wells Fargo|
Subscribe for More Information
|August 18, 2014|
|07:22 EDT||AEP||Silver Spring Network outlook has improved, says Stifel|
After meeting with Silver Spring's (SSNI) management, Stifel is more upbeat on the company's positioning for additional international and domestic opportunities, and on its execution. The firm is not concerned about the impact of possible delays of the company's deployment in conjunction with American Electric (AEP). Stifel expects Silver Spring's EPS to reach 92c in 2016, and it keeps a $16 price target and Buy rating on Silver Spring.